Pharming Group NV expected to post earnings of 1 cent a share - Earnings Preview

Pharming

11/03/2025 06:02

Pharming Group NV PHAR.AS  is expected to show a fall in quarterly revenue when it reports  results on March 13 for the period ending December 31 2024

The Leiden Zuid-holland-based  company is expected to report a 0.6% decrease in revenue to $80.743 million from $81.22 million a year ago, according to the mean estimate from 3 analysts, based on LSEG data.

‚ÄčLSEG's mean analyst estimate for Pharming Group NV is for earnings of 1 cent per share.

The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 4 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."

The mean earnings estimate of analysts was unchanged in the last three months. ‚Äč

Wall Street's median 12-month price target for Pharming Group NV is ‚ā¨2.10‚Äč, above‚Äč its last closing price of ‚ā¨0.74. ‚Äč‚Äč‚Äč

Previous quarterly performance (using preferred earnings measure in US dollars). ‚Äč

QUARTER ENDING
STARMINESMARTESTIMATE¬ģ
LSEG IBES ESTIMATE
ACTUAL
BEAT, MET, MISSED
SURPRISE %
Sep. 30 2024
0.00
0.00
0.00
Met
20
Jun. 30 2024
0.02
0.01
-0.01
Missed
-200
Mar. 31 2024
0.01
0.01
-0.02
Missed
-371.4‚Äč
Dec. 31 2023
0.01
0.00
Missed
-140
‚Äč‚ÄčSep. 30 2023
-0.03
-0.03
0.01
Beat
119.2
Jun. 30 2023
-0.02
-0.01
0.00
Beat
100‚Äč
Mar. 31 2023
-0.01
-0.01
-0.02
Missed
-161.5
Dec. 31 2022
0.01
0.01
-0.02
Missed
-440.1

This summary was machine generated March 11 at 06:02 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)